FDA re­jects Sesen Bio's blad­der can­cer pitch, send­ing shares spi­ral­ing back to pen­ny stock ter­ri­to­ry

Sesen Bio re­ceived some bad news Fri­day af­ter­noon that it said was “un­ex­pect­ed,” briefly slash­ing shares by more than 80% and be­low $1 for the first time in near­ly a year.

The biotech re­port­ed it re­ceived a CRL from the FDA re­gard­ing its blad­der can­cer can­di­date Vicineum, an an­ti­body-drug con­ju­gate ac­quired in the com­pa­ny’s buy­out of Toron­to-based Viven­tia back in 2016. Trad­ing was halt­ed for about an hour on Fri­day, with Sesen en­ter­ing the halt at about $6 per share and emerg­ing bat­tered with a $0.86 stock price.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER